SoCalBio Annual Investor & Partnering Conference Celebrates its 26th Successful Year as Greater Los Angeles’ Biotech/Medtech Industry’s Most Influential Event
October 29, 2024 10:00 ET
|
Southern California Biomedical Council
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Southern California Biomedical Council (SoCalBio) is proud to conclude the 2024 26th Annual Investor & Partnering Conference in Newport Beach, held...
Er-Kim CEO Cem Zorlular Recognized as a Patient Champion on the 2024 PharmaVoice 100
October 15, 2024 07:00 ET
|
Er-Kim
Cem Zorlular, CEO of Er-Kim recognized as a patient champion in this year's PharmaVoice100
SoCalBio’s 26th Annual Two-Day Investor Partnership Conference hosted at the Hyatt Regency Newport Beach for the Medical Device and Biotechnology Industry
September 18, 2024 13:14 ET
|
Southern California Biomedical Council
The Southern California Biomedical Council announced the full lineup of speakers and presenting companies for its 26th Annual SoCalBio Investor Conference.
BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action
May 31, 2024 20:59 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
May 10, 2024 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
March 19, 2024 06:30 ET
|
Centogene NV
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 ...
CENTOGENE Explores Strategic Alternatives
February 28, 2024 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
CENTOGENE Receives French Research Tax Credit Accreditation
January 24, 2024 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
December 13, 2023 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
April 11, 2023 06:30 ET
|
Centogene NV
The global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) Diagnosis...